CVS Health (NYSE:CVS) Director Larry Robbins Sells 1,018,000 Shares

CVS Health Corporation (NYSE:CVS) Director Larry Robbins sold 1,018,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $93.82, for a total transaction of $95,508,760.00. Following the completion of the transaction, the director directly owned 5,195,261 shares of the company’s stock, valued at approximately $487,419,387.02. The trade was a 16.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Larry Robbins also recently made the following trade(s):

• On Thursday, May 21st, Larry Robbins sold 370,462 shares of CVS Health stock. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90.
• On Tuesday, May 19th, Larry Robbins sold 1,983,538 shares of CVS Health stock. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10.

CVS Health Price Performance

Shares of NYSE CVS opened at $93.35 on Friday. The company has a fifty day moving average price of $80.03 and a 200 day moving average price of $78.98. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $98.43. The firm has a market cap of $119.11 billion, a PE ratio of 41.12, a PEG ratio of 0.91 and a beta of 0.60.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same period in the previous year, the firm posted $2.25 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health’s payout ratio is 117.18%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CVS. Sei Investments Co. boosted its position in CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after purchasing an additional 134,535 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of CVS Health by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after purchasing an additional 13,329 shares during the period. Treasurer of the State of North Carolina lifted its stake in shares of CVS Health by 1.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after buying an additional 7,588 shares during the last quarter. HUB Investment Partners LLC boosted its holdings in shares of CVS Health by 25.0% during the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after buying an additional 3,011 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in shares of CVS Health by 8.0% during the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock worth $111,017,000 after buying an additional 119,439 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CVS has been the topic of several analyst reports. Wells Fargo & Company boosted their price target on shares of CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. boosted their price target on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Bank of America cut their price target on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, January 27th. Morgan Stanley boosted their price target on shares of CVS Health from $93.00 to $106.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Finally, Leerink Partners reissued an “outperform” rating and set a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $98.68.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Glenview Capital said its CVS position has produced about an 80% total return since May 2024, signaling continued investor confidence in CVS’s long-term turnaround and helping reinforce the bullish case. Glenview Capital Issues Statement on CVS Health
• Positive Sentiment: Recent company-news items highlighting community programs, military support, and affordable senior housing may modestly support CVS’s brand and long-term ESG narrative, though they are unlikely to move the stock as much as the legal headlines. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Neutral Sentiment: Director Larry Robbins disclosed large stock sales over several days, including a roughly $187 million sale and other sizable transactions, but he still retains a large stake; the filings may be read as routine diversification rather than a full exit. SEC Form 4 filing
• Negative Sentiment: Hospitals allege CVS and its affiliates secretly captured 340B savings, which could lead to litigation costs, potential settlements, and tighter oversight of CVS’s pharmacy-benefit operations. Hospitals allege contracted CVS Health subsidiaries pocketed their 340B savings
• Negative Sentiment: Separate reports from the University of Michigan and University of Kansas hospital systems expanded the dispute and added to concerns that CVS could face multiple 340B-related lawsuits and rising legal exposure. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.